Chelsea Anderson1, Andrew B Smitherman2, Hazel B Nichols1. 1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2. Division of Pediatric Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014. They estimated 5-year relative survival at the time of diagnosis and at each additional year survived up to 25 years after diagnosis, conditional on the individual being alive at the beginning of that year. RESULTS: A total of 205,954 AYA patients with cancer were identified. Thyroid cancer, melanoma, testicular cancer, breast cancer, lymphoma, leukemia, and central nervous system (CNS) tumors comprised 67% of all cancers. For all cancers combined, 5-year relative survival was 84.5% (95% confidence interval, 84.3%-84.7%) at 1 year after diagnosis and 94.0% (95% CI, 93.9%-94.2%) at 5 years. The relative survival first exceeded 95%, reflecting minimal excess mortality compared with the general population, at 7 years. Patients with thyroid cancer, testicular cancer, melanoma, and breast cancer reached a relative survival of >95% at the time of diagnosis and at 1, 3, and 18 years after diagnosis, respectively. Estimates for those with Hodgkin lymphoma and leukemia were >95% at 6 and 13 years, respectively, but declined to <95% at 20 years. AYA individuals with CNS tumors did not reach 95% by 25 years after diagnosis. CONCLUSIONS: For AYA survivors of breast cancer, CNS tumors, and hematologic malignancies, long-term excess mortality should be considered when planning follow-up care. Cancer 2018;124:3037-43.
BACKGROUND: Many studies have examined long-term outcomes after childhood cancer, but few address outcomes for adolescent and young adult (AYA; those aged 15-39 years) cancer survivors. Conditional survival reflects changing mortality risk with time since cancer diagnosis and is a useful measure for planning long-term follow-up care. METHODS: Using the Surveillance, Epidemiology, and End Results registry 9 database, the authors identified a cohort of AYA patients diagnosed with a first malignant cancer between 1973 and 2009 and followed through 2014. They estimated 5-year relative survival at the time of diagnosis and at each additional year survived up to 25 years after diagnosis, conditional on the individual being alive at the beginning of that year. RESULTS: A total of 205,954 AYA patients with cancer were identified. Thyroid cancer, melanoma, testicular cancer, breast cancer, lymphoma, leukemia, and central nervous system (CNS) tumors comprised 67% of all cancers. For all cancers combined, 5-year relative survival was 84.5% (95% confidence interval, 84.3%-84.7%) at 1 year after diagnosis and 94.0% (95% CI, 93.9%-94.2%) at 5 years. The relative survival first exceeded 95%, reflecting minimal excess mortality compared with the general population, at 7 years. Patients with thyroid cancer, testicular cancer, melanoma, and breast cancer reached a relative survival of >95% at the time of diagnosis and at 1, 3, and 18 years after diagnosis, respectively. Estimates for those with Hodgkin lymphoma and leukemia were >95% at 6 and 13 years, respectively, but declined to <95% at 20 years. AYA individuals with CNS tumors did not reach 95% by 25 years after diagnosis. CONCLUSIONS: For AYA survivors of breast cancer, CNS tumors, and hematologic malignancies, long-term excess mortality should be considered when planning follow-up care. Cancer 2018;124:3037-43.
Authors: Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; T Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Maryska L Janssen-Heijnen; Liza N van Steenbergen; Ewout Steyerberg; Otto Visser; Dirk K De Ruysscher; Harry J Groen Journal: J Thorac Oncol Date: 2012-03 Impact factor: 15.609
Authors: Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Mubarak M Al-Mansour; Turki M Al-Fayea; Meteb Al-Foheidi; Ali M Bayer; Osama A Elmasri Journal: Lung Date: 2012-10-06 Impact factor: 2.584
Authors: Sharon H Giordano; Yong-Fang Kuo; Jean L Freeman; Thomas A Buchholz; Gabriel N Hortobagyi; James S Goodwin Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Maryska L G Janssen-Heijnen; Adam Gondos; Freddie Bray; Timo Hakulinen; David H Brewster; Hermann Brenner; Jan-Willem W Coebergh Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Graça M Dores; Catherine Metayer; Rochelle E Curtis; Charles F Lynch; E Aileen Clarke; Bengt Glimelius; Hans Storm; Eero Pukkala; Flora E van Leeuwen; Eric J Holowaty; Michael Andersson; Tom Wiklund; Timo Joensuu; Mars B van't Veer; Marilyn Stovall; Mary Gospodarowicz; Lois B Travis Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: L N van Steenbergen; M Steur; V E P P Lemmens; H J T Rutten; D J van Spronsen; M L G Janssen-Heijnen Journal: Eur J Cancer Date: 2012-09-08 Impact factor: 9.162
Authors: Chelsea Anderson; Jennifer L Lund; Mark A Weaver; William A Wood; Andrew F Olshan; Hazel B Nichols Journal: Cancer Date: 2019-03-20 Impact factor: 6.860
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984
Authors: Amy M Berkman; Clark R Andersen; Branko Cuglievan; David C McCall; Philip J Lupo; Susan K Parsons; Courtney D DiNardo; Nicholas J Short; Nitin Jain; Tapan M Kadia; J A Livingston; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090
Authors: Jae Seung Lee; In Rae Cho; Hye Won Lee; Mi Young Jeon; Tae Seop Lim; Oidov Baatarkhuu; Do Young Kim; Kwang-Hyub Han; Jun Yong Park Journal: Cancer Res Treat Date: 2019-02-12 Impact factor: 4.679
Authors: Amy M Berkman; J A Livingston; Kelly Merriman; Michelle Hildebrandt; Jian Wang; Seyedeh Dibaj; Jennifer McQuade; Nancy You; Anita Ying; Carlos Barcenas; Diane Bodurka; April DePombo; Hun Ju Lee; John de Groot; Michael Roth Journal: Cancer Date: 2020-06-02 Impact factor: 6.860
Authors: Chelsea Anderson; Victoria L Bae-Jump; Russell R Broaddus; Andrew F Olshan; Hazel B Nichols Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-03-18 Impact factor: 4.090
Authors: Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Eduardus F M Posthuma; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed Journal: Blood Cancer J Date: 2021-01-13 Impact factor: 11.037
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254